iPLATO awarded £1.7m SBRI contract to drive health equity and improve bowel cancer screening rates
May 31, 2023
A Year to Remember: Reflecting on 2024 at iPLATO
By Tobias Alpsten, CEO and Founder of iPLATO
As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.
The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.
What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.
This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.
Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.
We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.
We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.
Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.
We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.
Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together!
Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.
This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.
In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.
Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.
iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.
With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.
Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.
As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health.
Here’s to 2025!
Tobias
© 2026 iPLATO. All rights reserved
iPLATO awarded £1.7m SBRI contract to drive health equity and improve bowel cancer screening rates
May 31, 2023
A Year to Remember: Reflecting on 2024 at iPLATO
By Tobias Alpsten, CEO and Founder of iPLATO
As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.
The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.
What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.
This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.
Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.
We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.
We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.
Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.
We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.
Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together!
Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.
This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.
In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.
Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.
iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.
With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.
Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.
As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health.
Here’s to 2025!
Tobias
© 2026 iPLATO. All rights reserved

/
iPLATO awarded £1.7m SBRI contract to drive health equity and improve bowel cancer screening rates
iPLATO awarded £1.7m SBRI contract to drive health equity and improve bowel cancer screening rates
May 31, 2023
The NHS distributes free Faecal Immunochemical Test (FIT) kits to people aged 60 to 74 in England who are registered with a GP practice. Age eligibility is currently being lowered to include people from 50. The kit detects small amounts of blood in poo that is not visible but may signal the presence of polyps or bowel cancer. Pre-Covid, the return rate of FIT kits was 56% in South East London against a national target of 75%. Some groups have persistently lower uptake than the rest of the population; these include non-white people, those for whom English isn’t their first language, people with a severe mental health condition, and those with learning disabilities.
SBRI Healthcare supports the development of innovations which meet known NHS challenges. Bowel cancer is the 4th most common cancer, costing the UK £1.74 billion annually. The programme will be delivered in partnership with the South East London Cancer Alliance (SELCA) and local community leaders, academics and primary care professionals to establish the optimal communication channels and content to engage these ‘hard-to-reach’ groups using iPLATO’s platform which will provide tailored education through mobile messaging, ensuring scalability and privacy.
Tobias Alpsten, Founder and CEO of iPLATO said:
“Digital technologies hold great promise for making cancer screening and care accessible to everyone, and to reduce health inequities they must be developed in collaboration with the people they serve. This ground-breaking initiative will deliver better access to bowel cancer identification and preventative care measures for many vulnerable patients.”
Pastor Modupe Afolabi, Executive Director, Redeemed Christian Church of God, said: “I welcome this important programme which I strongly believe is the start of an important health initiative within our community.”
Representing SELCA, Professor Arnie Purushotham, Director of King’s Health Partners Cancer Centre at King’s College London and Consultant Surgeon at Guy’s and St Thomas’ NHS?Foundation Trust, said: “I believe this innovative collaboration with iPLATO will meaningfully benefit these four patient groups. We know that early identification of cancer has the greatest impact on cancer survival”.
“Screening is a vital public health strategy for the early identification of cancers because it enables more timely access to treatment which can improve clinical outcomes and survival. We could not have put together a project of this scale aimed at benefiting hard-to-reach groups without the partnership of SELCA and lay partners, and we believe this work will be relevant in other parts of the country and for other screening programmes.”
Dr Simon Chowdhury, Huma’s Cancer Lead and Oncologist
Disclaimer: This work was commissioned and funded by the NHS Cancer Programme, with the support of SBRI Healthcare and the NHS Accelerated Access Collaborative. The views expressed in the publication are those of the author(s) and not necessarily those of the NHS Cancer Programme or its stakeholders.
© 2026 iPLATO. All rights reserved